文献速递MDS 与骨髓增殖性肿瘤

IFNα对骨髓增殖性肿瘤突变造血干祖细胞动态的影响

Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.
PubMed 文献 · Blood · 2021-01-01

该前瞻性纵向观察研究对48例MPN患者随访超过5年,通过84 845次早期和晚期造血祖细胞克隆结构测量及409次成熟细胞变异等位基因频率测量,结合数学建模和分层贝叶斯推断,分析IFNα靶向突变HSC的动态。结果显示IFNα通过诱导JAK2V617F HSC退出静息并分化为祖细胞发挥作用,疗效在同合子JAK2V617F HSC中高于杂合子,且杂合子中高剂量IFNα疗效增加;CALRm HSC反应异质,1型和2型CALRm间不同,高剂量IFNα与更差结局相关。

要点

  • IFNα靶向JAK2V617F HSC的机制涉及诱导其退出静息并分化为祖细胞。
  • 同合子JAK2V617F HSC对IFNα的疗效高于杂合子,杂合子中高剂量IFNα疗效增加。
  • CALRm HSC对IFNα反应异质,高剂量IFNα与更差结局相关。

核心结论

  • IFNα的长期分子疗效提示HSC耗竭机制,且取决于驱动突变类型和IFNα剂量。

研究设计与样本

  • 前瞻性纵向观察研究,纳入48例MPN患者,随访超过5年。
  • 测量早期和晚期造血祖细胞克隆结构84 845次,成熟细胞全局变异等位基因频率409次,每年多次。
  • 采用数学建模和分层贝叶斯推断分析IFNα靶向突变HSC的动态。

主要发现

  • IFNα靶向JAK2V617F HSC通过诱导其退出静息并分化为祖细胞。
  • 同合子JAK2V617F HSC的治疗疗效高于杂合子。
  • 杂合子JAK2V617F HSC中,高剂量IFNα疗效增加。
  • CALRm HSC对IFNα的分子反应异质,1型和2型CALRm间不同,高剂量IFNα与更差结局相关。

临床怎么用

  • 对于JAK2V617F MPN患者,IFNα疗效与JAK2V617F合子状态相关,同合子者疗效更高。
  • 杂合子JAK2V617F患者中,高剂量IFNα可能增加疗效。
  • CALRm患者中IFNα疗效异质,高剂量IFNα可能与更差结局相关,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Classical BCR-ABL-negative myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells (HSCs) caused mainly by recurrent mutations in genes encoding JAK2 (JAK2), calreticulin (CALR), or the thrombopoietin receptor (MPL). Interferon α (IFNα) has demonstrated some efficacy in inducing molecular remission in MPNs. To determine factors that influence molecular response rate, we evaluated the long-term molecular efficacy of IFNα in patients with MPN by monitoring the fate of cells carrying driver mutations in a prospective observational and longitudinal study of 48 patients over more than 5 years. We measured the clonal architecture of early and late hematopoietic progenitors (84 845 measurements) and the global variant allele frequency in mature cells (409 measurements) several times per year. Using mathematical modeling and hierarchical Bayesian inference, we further inferred the dynamics of IFNα-targeted mutated HSCs. Our data support the hypothesis that IFNα targets JAK2V617F HSCs by inducing their exit from quiescence and differentiation into progenitors. Our observations indicate that treatment efficacy is higher in homozygous than heterozygous JAK2V617F HSCs and increases with high IFNα dose in heterozygous JAK2V617F HSCs. We also found that the molecular responses of CALRm HSCs to IFNα were heterogeneous, varying between type 1 and type 2 CALRm, and a high dose of IFNα correlates with worse outcomes. Our work indicates that the long-term molecular efficacy of IFNα implies an HSC exhaustion mechanism and depends on both the driver mutation type and IFNα dose.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mosca M, Hermange G, Tisserand A, et al. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms. Blood. 2021. PMID: 34407546. doi:10.1182/blood.2021010986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。